

HEALEY ALS Platform Trial

Weekly Q&A – April 15, 2021



Guest Speaker

Adam Quick, MD

**The Ohio State University Wexner Medical Center, Columbus OH
Platform Trial Site Investigator**





Erin Cohen




Sarah Heintzman, CNP

THE OHIO STATE UNIVERSITY
WEXNER MEDICAL CENTER



Adam Quick, MD



Stephen Kolb, MD, PhD

The Ohio State University Wexner Medical Center

Healey Platform Trial Site #762
Columbus Ohio

Contact us via any of the following:

Email: Erin.Cohen@osumc.edu; Sarah.Heintzman@osumc.edu;

Adam.Quick@osumc.edu


Phone: 614-685-5661



Perpetual Adaptive Trial

Randomization Ratio 3:1; Shared Placebo

Open Label Extension (OLE) offered




How to Find a Center Near You

Sean M. Healey & AMG
Center for ALS

About the Healey Center Clinical Care Patient & Family Resources

Map of Participating Sites

HEALEY ALS Platform Trial Locations
This map was created by a user. Learn how to create your own.




List of Participating Sites by State

Site	State	Contact Information
Barrow Neurological Institute	Arizona	Jessie Duncan

51 sites are actively enrolling

Contact Info of Participating Sites by State



<https://www.massgeneral.org/neurology/als/research/platform-trial-sites>

List of enrolling sites as of April 15, 2021

51 sites are enrolling

- ✓ Texas Neurology
- ✓ Mass General Hospital
- ✓ UTHSCSA
- ✓ Hospital for Special Care
- ✓ Holy Cross Hospital
- ✓ Thomas Jefferson
- ✓ Houston Methodist
- ✓ Henry Ford Health System
- ✓ Barrow Neurological Institute
- ✓ Ohio State University
- ✓ Northwestern University
- ✓ University of Chicago
- ✓ Wake Forest
- ✓ University of Nebraska
- ✓ Loma Linda University
- ✓ University of Washington
- ✓ University of Iowa
- ✓ Washington University
- ✓ University of Pennsylvania
- ✓ University of Michigan
- ✓ California Pacific Medical Center
- ✓ Penn State Hershey
- ✓ UMass Worcester
- ✓ University of Miami
- ✓ University of Colorado
- ✓ Cedars-Sinai
- ✓ University of Florida
- ✓ University of South Florida
- ✓ Columbia University
- ✓ University of Virginia
- ✓ Emory University
- ✓ University of Maryland
- ✓ SUNY Upstate
- ✓ Beth Israel Deaconess
- ✓ Temple University
- ✓ Dartmouth-Hitchcock
- ✓ Medical College of Wisconsin
- ✓ Spectrum Health
- ✓ University of Missouri
- ✓ University of Minnesota
- ✓ Johns Hopkins University
- ✓ University of CA Irvine
- ✓ University of Kansas
- ✓ Vanderbilt University
- ✓ University of Kentucky
- ✓ Mayo Rochester
- ✓ Duke University
- ✓ Neurology Associates
- ✓ Ochsner Health System
- ✓ Mayo Clinic Florida
- ✓ [St. Louis University](#)

Enrollment Updates (as of April 15, 2021)

- **432** individuals with ALS signed informed consent
- **332** individuals were assigned to a regimen
- **294** are receiving investigational product (active or placebo)
- **68** have entered Open Label Extension (OLE)

Thank You

This breakthrough trial would not be possible without your participation

Your **partnership** in research is what keeps us filled with passion, dedication, and the commitment to uncover new promising treatments for ALS

Every research participant, whether on the active drug or placebo, plays a critical role in making the hope of finding a cure for ALS a reality

For More Updates

- **Weekly webinars**

The idea of came from our Patient Advisory Committee: we are excited to be talking with you on a weekly basis and take any questions you might have

- **Find the schedule and registration links on our website**

<https://www.massgeneral.org/neurology/als/research/platform-trial-news/>

Previously: Drug mechanism of action and science webinars

Jan 21- Prilenia/Pridopidine (view recording- <https://bit.ly/3ad3qel>)

Feb 4 - Clene/CNM-Au8 (view recording- <https://bit.ly/3jB3WWt>)

Feb 18- Biohaven/Verdiperstat (view recording- <https://bit.ly/301qdDR>)

Feb 25- UCB/Zilucoplan (view recording- <https://bit.ly/3b3cpyS>)



Previously: Drug Development NEALS Webinar Series

This series will include talks on the preclinical development of potential therapies, the regulatory pathway, the science of trials, the clinical trial site level overview, and the importance of patient engagement.

Part 1: Scientific Considerations (Recorded)

April 7th 12:00-1:00pm EDT

Part 2: Regulatory Considerations (Recorded)

April 9th 12:30-1:30pm EDT



View recordings at <https://bit.ly/3frQsfB>

Send us webinar ideas!

- Biomarkers
- Biostatistics / Trial Design
- Get to know our sites



Next Week's Guest: Dr. Daragh Heitzman from Texas Neurology



Patient Navigator



Catherine Small

Allison Bulat

Phone: 833-425-8257 (HALT ALS)

E-mail: healeyalsplatform@mgh.harvard.edu



To see whether you might qualify, view the list of eligibility criteria online:

<https://bit.ly/3p4PrLL>